To the best of our knowledge, despite the proliferative potential of thyroid hormones and sex steroids, there is currently no evidence supporting worse cancer or tumor outcomes when CCS with established deficiencies in these hormones are treated at substitutive doses. The gene discussed is TG; the disease is neoplasm.